ArticleTherapeutic advances in medical oncology2024

Safety of dostarlimab in combination with chemotherapy in patients with primary advanced or recurrent endometrial cancer in a phase III, randomized, placebo-controlled trial (ENGOT-EN6-NSGO/GOG-3031/RUBY).

Annika Auranen et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.